These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 6220231)

  • 21. [Effect of peripheral vasodilators on thrombocyte aggregation in chronic circulatory insufficiency].
    Kirichenko LL; Gaĭdukova NI; Solov'eva FV
    Sov Med; 1986; (2):91-4. PubMed ID: 3704769
    [No Abstract]   [Full Text] [Related]  

  • 22. Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
    Saito S; Ichikawa M; Ozawa Y; Yumikura S; Nagasawa M; Hibiya K; Tamura Y; Tomobe K; Hatano M
    Jpn Circ J; 1984 Apr; 48(4):350-6. PubMed ID: 6425526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic use of vasodilators in the therapy of congestive cardiac insufficiency].
    Manfrin M; Frascione P; Budini A; Cesari GP; Colonna PL; Schicchi F; Chiesa R
    Minerva Med; 1982 Oct; 73(40):2741-4. PubMed ID: 7133486
    [No Abstract]   [Full Text] [Related]  

  • 24. [Vasodilator effects of intravenous isosorbide dinitrate in patients with heart failure--multi-center studies].
    Hirosawa K; Kimata S; Kawai C; Kambara H; Hosoda S; Hayakawa H; Takano T; Yamaguchi H; Inoue M; Hiramori K
    Kokyu To Junkan; 1985 Jul; 33(7):903-12. PubMed ID: 3903903
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevention of nitrate tolerance with concomitant administration of hydralazine.
    Elkayam U
    Can J Cardiol; 1996 May; 12 Suppl C():17C-21C. PubMed ID: 8634919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
    Ferdinand KC
    J Law Med Ethics; 2008; 36(3):458-63. PubMed ID: 18840236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
    Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI1-4. PubMed ID: 8500232
    [No Abstract]   [Full Text] [Related]  

  • 29. [Systolic intervals in dilated heart insufficiency. Influence of vasodilator treatment].
    González-Juanatey JR; Amaro Cendón A; Vega Fernández M; Gil de la Peña M
    Med Clin (Barc); 1988 Jan; 90(3):93-6. PubMed ID: 3280894
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute and chronic isosorbide dinitrate therapy in congestive heart failure: demonstration of improved exercise capacity and differing arterial and venous tolerance during chronic administration.
    Leier CV; Huss P; Magorien RD; Unverferth DV
    Z Kardiol; 1983; 72 Suppl 3():173-7. PubMed ID: 6666218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of isosorbide dinitrate in management of chronic congestive heart failure.
    Parmley WW
    Am Heart J; 1985 Jul; 110(1 Pt 2):264-8. PubMed ID: 3893081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure.
    Franciosa JA
    Prog Cardiovasc Dis; 1982; 24(4):319-30. PubMed ID: 7034048
    [No Abstract]   [Full Text] [Related]  

  • 33. [Chronic heart failure and vasodilator therapy].
    Ito T; Matsumoto S; Ito Y
    Nihon Rinsho; 1978 Nov; 36(11):3565-72. PubMed ID: 366206
    [No Abstract]   [Full Text] [Related]  

  • 34. Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?
    Packer M; Lee WH; Kessler PD; Gottlieb SS
    J Cardiovasc Pharmacol; 1987; 9 Suppl 2():S73-5. PubMed ID: 2441205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of peripheral vasodilators on pulmonary respiratory function and the indices of bicycle spiroergometry in heart failure patients].
    Ordian MM; Sobol' IuS; Kassirskiĭ SG
    Ter Arkh; 1987; 59(5):56-60. PubMed ID: 3616945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute and chronic cardiac decompensation: is vasodilator therapy useful?].
    Malacco E; Limonta A; Milanesi A; Micossi P
    Minerva Med; 1982 Jan; 73(1-2):25-32. PubMed ID: 7058000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydralazine and nitrates: beyond race and ethnicity.
    Ghali JK
    J Card Fail; 2007 Apr; 13(3):238. PubMed ID: 17448423
    [No Abstract]   [Full Text] [Related]  

  • 38. [Premises on the use of vasodilator agents. The venous or mixed vasodilators].
    Prati PL; Pezzella A; Di Lorenzo M; Barbis V; Manfrin M; Giovannini E; Gambelli G; Signoretti P; Pittorino L; Greco C
    G Ital Cardiol; 1979; 9 Suppl 1():18-20. PubMed ID: 548300
    [No Abstract]   [Full Text] [Related]  

  • 39. [What is the value of organic nitrate preparations in treatment of chronic heart failure?].
    Internist (Berl); 1996 Jul; 37(7):739. PubMed ID: 8830005
    [No Abstract]   [Full Text] [Related]  

  • 40. Hemodynamic effects of vasodilator therapy in severe left heart failure combined with large atrial septal defects.
    Kolibash AJ; Magorien RD; Robinson JL; Leier CV
    Am J Med; 1982 Sep; 73(3):439-4. PubMed ID: 7124771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.